CoChat

Post‐ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia

Open access
Wang, Y, Zhang, Z G, Rhodes, K, Renzi, M, Zhang, R L, Kapke, A, Lu, M, Pool, C, Heavner, G, Chopp, M · 2007 · British Journal of Pharmacology
Cited by 136

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Background and purpose: Recombinant human erythropoietin (rhEPO; Epoetin‐α; PROCRIT™) has been shown to exert neuroprotective and restorative effects in a variety of CNS injury models. However, limited information is available regarding the dose levels required for these beneficial effects or the neuronal responses that may underlie them. Here we have investigated the dose‐response to rhEPO and compared the effects of rhEPO with those of carbamylated rhEPO (CEPO) in a model of cerebral stroke in rats. Experimental approach: Rats subjected to embolic middle cerebral artery occlusion (MCAo) were treated with rhEPO or CEPO, starting at 6 h and repeated at 24 and 48 h, after MCAo. Cerebral infarct volumes were assessed at 28 days and neurological impairment at 7, 14, 21 and 28 days, post‐MCAo. Key results: rhEPO at dose levels of 500, 1150 or 5000 IU kg−1 or CEPO at a dose level of 50 μ g kg−1 significantly reduced cortical infarct volume and reduced neurologic impairment. All doses of rhEPO, but not CEPO, produced a transient increase in haematocrit, while rhEPO and CEPO substantially reduced the number of apoptotic cells and activated microglia in the ischemic boundary region. Conclusions and implications: These data indicate that rhEPO and CEPO have anti‐inflammatory and anti‐apoptotic effects, even with administration at 6 h following embolic MCAo in rats. Taken together, these actions of rhEPO and CEPO are likely to contribute to their reduction of neurologic impairment following cerebral ischemia. British Journal of Pharmacology (2007) 151, 1377–1384; doi:10.1038/sj.bjp.0707285

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjp.0707285

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke

    Chen, J., Zhang, Z. G., Li, Y., Wang, Y., Wang, L., Jiang, H., Zhang, C., Lu, M., Katakowski, M., Feldkamp, C. S., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10555 · Cited by 538 · cited 3×

    “To examine whether treatment with rhEPO or CEPO improves neurobehavioural outcome, we performed a battery of behavioural tests that are sensitive to sensorimotor impairment in rodents (Li et al., 2000; Chen et al., 2003; Zhang et al., 2003, 2004, 2005; Wang et al., 2004).”
    BackgroundSelf-citation
  • Erythropoietin as an antiapoptotic, tissue-protective cytokine

    Ghezzi, P., & Brines, M. (2004) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401450 · Cited by 327 · cited 1×

    “Delayed treatment with rhEPO or CEPO reduces apoptosis and microglial activation Previous studies have reported that acute treatment with rhEPO prevents neuronal apoptosis and reduces activation of inflammatory cells within the CNS (Siren et al., 2001; Ghezzi and Brines, 2004).”
    Background

Metadata

Authors
Wang, Y., Zhang, Z. G., Rhodes, K., Renzi, M., Zhang, R. L., Kapke, A., Lu, M., Pool, C., Heavner, G., & Chopp, M.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2007-08
Volume
151
Issue
8
Pages
1377-1384
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W1514245259
Cited by
136
References
2
FWCI
10.03
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.